Literature DB >> 18796252

Genetic determinants of phenotype in beta-thalassemia.

Inusha Panigrahi1, Sarita Agarwal.   

Abstract

Modifier genes are defined as inherited genetic variation that leads to a qualitative or quantitative difference in disease phenotype. This has made the prediction of the phenotype based upon the genotype more difficult. Beta-thalassemia phenotype is modified by co-existent other genetic alterations. Changes alpha/beta-globin ratio can either ameliorate the disease phenotype or increase the severity of the disease in beta-thalassemia. Primary modifiers primarily affecting the clinical presentation include alpha gene changes, XmnI polymorphism and hereditary persistence of fetal hemoglobin (HPFH) variants. 'Thalassemia intermedia' is a heterogenous group with interplay of several genetic factors. The nature of the beta-genotype as well as the knowledge of the presence or absence of alleviating factors help the physician to decide on commencement of a regular transfusion regime or other lines of management including hydroxyurea therapy. The secondary modifiers affect the severity of jaundice, bone disease, cardiac and thrombotic complications. The present review gives a concise discussion of various modifying genes and the influence on the phenotype of beta-thalassemia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18796252     DOI: 10.1179/102453308X316031

Source DB:  PubMed          Journal:  Hematology        ISSN: 1024-5332            Impact factor:   2.269


  4 in total

Review 1.  Stress erythropoiesis: new signals and new stress progenitor cells.

Authors:  Robert F Paulson; Lei Shi; Dai-Chen Wu
Journal:  Curr Opin Hematol       Date:  2011-05       Impact factor: 3.284

2.  Pregnancy and Childbirth: An Unexpected Cakewalk for a Mother With Beta Thalassemia Major Homozygous for IVS (G-C) Mutation.

Authors:  Mousumi D Ghosh; Mamta R Datta; Vinita Singh; Farah Rana
Journal:  Cureus       Date:  2021-03-13

3.  beta-Thalassaemia Major in a Spanish Patient due to a Compound Heterozygosity for CD39 C --> T/-28 A --> C.

Authors:  Soledad Gamarra; Guillermo Garcia-Effron; Carmen Monteserin; Isabel Lopez-Villar; Florinda Gilsanz; Joaquín Martinez-Lopez
Journal:  Adv Hematol       Date:  2009-07-28

Review 4.  Gene Therapy for Hemoglobinopathies.

Authors:  Marina Cavazzana; Fulvio Mavilio
Journal:  Hum Gene Ther       Date:  2018-10       Impact factor: 5.695

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.